Related Experiment Video
Updated: Feb 12, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Emerging Therapies in Metastatic Prostate Cancer
Daniel W Sonnenburg1, Alicia K Morgans2
1Northwestern University Feinberg School of Medicine, Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, 676 N. St. Clair St., Chicago, IL, 60611, USA.
Purpose Of Review:
In the last decade, there have been multiple landmark therapeutic advances for the treatment of metastatic prostate cancer, both in the castration-resistant and hormone-sensitive setting. In this review, we highlight recent progress and ongoing trials for metastatic prostate cancer, including advances in chemotherapy, androgen receptor-directed therapy, targeted therapies, and immunotherapy.
Recent Findings:
Several landmark studies for men with metastatic hormone-sensitive prostate cancer demonstrated improvement in overall survival with the addition of docetaxel chemotherapy or abiraterone acetate to standard androgen deprivation therapy. A single-arm phase 2 study of the PARP inhibitor olaparib demonstrated high response rates and more favorable progression-free and overall survival for men with metastatic castration-resistant prostate cancer and DNA repair defects treated with olaparib compared with men without DNA repair defects. Multiple ongoing clinical trials are investigating novel hormonal therapies and combinations of chemotherapy, targeted small molecules, immunotherapy, and radiopharmaceuticals. Progress continues to be made in the treatment of metastatic prostate cancer, and ongoing clinical trials continue to investigate novel agents and approaches to treatment.
Insights
Recent advances in metastatic prostate cancer treatment include chemotherapy and androgen receptor-directed therapies for hormone-sensitive and castration-resistant stages. Ongoing trials explore novel agents and combinations for improved patient outcomes.
Area of Science:
- Oncology
- Urology
Background:
- Metastatic prostate cancer treatment has seen significant therapeutic advancements in both hormone-sensitive and castration-resistant settings over the past decade.
- Key areas of progress include chemotherapy, androgen receptor-directed therapy, targeted therapies, and immunotherapy.
Purpose of the Study:
- To review recent therapeutic progress and ongoing clinical trials for metastatic prostate cancer.
- To highlight advances in various treatment modalities for advanced prostate cancer.
Main Methods:
- Review of landmark studies and ongoing clinical trials in metastatic prostate cancer treatment.
- Analysis of data from studies investigating chemotherapy, hormonal therapies, targeted agents, and immunotherapy.
Main Results:
- Addition of docetaxel chemotherapy or abiraterone acetate to androgen deprivation therapy improved overall survival in metastatic hormone-sensitive prostate cancer.
- Olaparib, a PARP inhibitor, showed high response rates and improved survival in metastatic castration-resistant prostate cancer with DNA repair defects.
- Numerous ongoing trials are evaluating novel hormonal therapies, chemotherapy combinations, targeted small molecules, immunotherapy, and radiopharmaceuticals.
Conclusions:
- Significant progress continues in the management of metastatic prostate cancer.
- Ongoing clinical trials are crucial for investigating novel agents and treatment strategies to further improve patient outcomes.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Emerging Adulthood
Introduction Cardiac Emergencies
Gene Therapy
Applications of GIS: Disaster Management and Emergency Response

